DGAP-Adhoc

Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21 - Seite 2

Revenue is expected to reach around EUR 1.6 billion (past year: EUR 1,335.5 million) in FY 2020/21. EBIT margin for FY 2020/21 is projected to reach a level of approximately 20% (past year: 13.3%), with significant support from lower than usual sales and marketing expenses in the current year. The company's mid-term margin outlook remains unchanged: to generate an EBIT margin sustainably above the level of 18%.    

 

Contact for investors and press
Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: [phone]
E-Mail: [e-mail]

 

^[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
^[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).
^[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).

---

19-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	Carl Zeiss Meditec AG
	Göschwitzer Str. 51-52
	07745 Jena, Germany
	Germany
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.zeiss.de/meditec-ag/ir
ISIN:	DE0005313704
WKN:	531370
Indices:	MDAX, TecDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1186148